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Summary 
Blocking the CD28-B7 T cell costimulatory pathway with the fusion protein CTLA4Ig inhibits 
alloimmune responses in vitro and in vivo and induces tolerance to cardiac allografts in mice 
and rats, but the mechanisms mediating the tolerant state in vivo are unknown. Here, we report 
the effects and potential mechanisms of CTLA4Ig in the rat renal allograft model.  LEW rats 
were nephrectomized and received  renal allografts from major histocompatibility complex-incompat- 
ible WF rats. While all untreated and control immunoglobulin (Ig)-treated animals acutely re- 
jected their allografts and died,  86%  of rats that received a single injection  of CTLA4Ig on 
day 2 after transplantation  had prolonged survival (>60-100 days) with preserved renal function. 
By contrast, only 29% of animals that received  CTLA4Ig on the day of  engraftment had prolonged 
survival. Long-term survivors (>100 days) exhibited donor-specific tolerance, accepting donor- 
matched WF but acutely rejecting third-party BN cardiac allografts. Immunohistological  anal- 
ysis of grafts sampled at 1 week after transplantation  showed that both control and CTLA4Ig- 
treated animals had mononuclear cell infiltrates, with a higher percentage of CD4 + cells in the 
CTLA4Ig-treated group. However, while this was associated with vasculitis and tubulitis in con- 
trol grafts,  there was no evidence of tissue injury in CTLA4Ig-treated animals. The immune 
response leading to graft rejection in control animals was characterized by expression of the T 
helper  (Th) type 1 cytokines  interleukin (IL)-2 and interferon-% In contrast,  the persistent 
CD4 § infiltrate  without graft rejection in CTLA4Ig-treated animals was associated with in- 
creased staining for the Th2-related cytokines IL-4 and Ibl0. Furthermore, grafts from CTLA4Ig- 
treated animals had marked upregulation of intragraft staining for IgG1, but not IgG2a or IgG2b. 
Administration of riD2 to CTLA4Ig-treated animals restored allograft rejection in 50% of animals 
tested. These results confirm that blockade of the CD28-B7  pathway after alloantigenic chal- 
lenge induces donor-specific acceptance of vascularized organ allografts, and indicates in this model 
that CTLA4Ig inhibits  Thl but spares Th2 cytokines in vivo. 
N 
'aive T cells require two distinct signals for activation. 
The first signal is provided by the engagement of the 
TCR with the MHC molecule plus peptide complex on APC, 
and the second costimulatory signal is provided by engage- 
ment of T cell surface receptors with their ligands on APC. 
Signaling through the TCR alone without a costimulatory 
signal leads to a prolonged state ofT cell anergy (1). Among 
the multiple costimulatory pathways identified, interaction 
of CD28 on T cells with either of two ligands, B7-1 or B7-2, 
on APC is the most important costimulatory pathway for 
the response to alloantigens (2). Ligation of CD28 by B7-1 
or B7-2 is blocked by CTLA4Ig, a recombinant fusion pro- 
tein that contains the extracellular domain of human CTLA-4 
(a gene highly homologous to CD28) fused to a human IgG1 
heavy chain (2). CTLA4Ig has a 20-fold higher affinity for 
B7-1 than does CD28,  and acts as a competitive  inhibitor 
of CD28  binding  to  B7-1 or  B7-2. Human  CTLA4Ig 
efficiently binds  to human, murine, and rat B7 molecules, 
and inhibits the alloimmune response in vitro (3, 4) and in 
vivo (3, 5, 6). Previously, we have shown that a single injec- 
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tion to rats that received donor splenocytes on the day of 
engraftment, induced donor-specific tolerance of the allografts 
(7). More recently, CTLA4Ig has been shown to induce toler- 
ance in the mouse cardiac allograft model (8). Despite this 
evidence that CTLA4Ig can induce tolerance, its mechanisms 
of action in vivo are unknown. We now report the effects 
and potential mechanisms of CD28-B7 costimulatory blockade 
by CTLA4Ig in a rat renal allograft model. 
Materials and Methods 
Animals.  Inbred  male WF  (RTI"),  LEW  (ILT11), and BN 
(RT1 n) strain rats, 8-12-wk old, were obtained from a commer- 
cial source (Harlan Sprague Dawley Inc., Indianapolis,  IN). 
Renal Transplantation and Graft Function.  LEW rats underwent 
bilateral nephrectomies and received MHC-incompatible WF renal 
allografts.  In this model animals typically suffer acute rejection, 
become oligoanuric,  and die from uremia within 2 wk (9). The 
survival time of the renal aUograft is defined as the time from trans- 
plantation to the time of death. Only animals dying from surgical 
technical failures within the first 24 h after transplantation were 
excluded from analysis. Renal allograft function was assessed by 
measuring serial serum creatinine levels at different time intervals 
after transplantation. Serum was obtained by tail vein puncture, 
and serum creatinine was measured by the alkaline picrate method. 
Antibodies and Other Reagents.  The fusion protein CTLA4Ig 
(Bristol-Myers Squibb Pharmaceutical Research Institute) has been 
previously described (2). Details of Abs and their use in immuno- 
histology were  described  previously  (10-12).  Unless  otherwise 
specified, all routine mAbs and monospecific polyclonal Abs were 
obtained commercially from Sera-Lab (Accurate  Chemicals  and 
Science Corp., Westbury, NY) or made by us (BWH-4 and 1D10). 
Abs were directed against all rat leucocytes (CD45, OX-1), T cells 
(TCR-(x/j8  chains, R73), CD4 (BWH-4, made by us) and CD8 
(OX-8) subsets, and macrophages (ED1). Activation of mononuclear, 
endothelial, or parenchymal  cells was assessed using Abs to class 
II MHC antigens (OX-3);  p55 chain of the IL-2R (CD25, ART- 
18, courtesy of Dr. T. Diamantstein, Free University, Berlin, Ger- 
many); intercellular  adhesion  molecule (ICAM-1,  CD54,  1A29) 
(Seikagaku America Inc., Rockville, MD) and the cytokines IL-2 
(1D10, made by us and will be made available for research use); 
IL-4 (BI~4P), II.,6 (LP-716) (Genzyrne Corp., Cambridge, MA); 
IL-10 (AB-417-NA) (R&D Systems, Inc., Minneapolis, MN); IFN-3, 
(DB-12, courtesy of Dr. P. van der Meide, TNO Primate Center, 
Rijswijk, Holland);  TNF-c~ (IP-300) (Genzyme Corp.) plus PGE2 
(Sigma Chemical Co., St. Louis, MO). Mouse hybridomas secreting 
mAbs to rat Ig isotypes were purchased from American Type Cul- 
ture Collection (ILockville, MD): RGll/39.4 (anti-IgG1, does not 
react with human IgG1, which is present in CTLA4Ig), RG7/1.30 
(anti-IgG2a),  and tLG7/11.1 (anti-IgG2b).  Polyclonal Abs to rat 
Ig-absorbed goat anti-mouse immunoglobulin were obtained from 
Sigma Chemical Co., and rabbit anti-goat Ig, goat peroxidase- 
antiperoxidase  (PAP), swine anti-rabbit Ig, and rabbit PAP were 
obtained from Dako Corp. (Carpinteria,  CA). 
Immunohistology.  Renal transplants (three/group) were harvested 
at day 7 or day >100 (allografts), or at day 7 (isografts), sliced into 
small pieces, quick-frozen in liquid nitrogen, and stored at -80~ 
in preparation for immunohistologic studies (9). Cryostat sections 
were fixed in paraformaldehyde-lysine-periodate for staining of leu- 
kocytes and activation antigens or fixed in acetone for localization 
of cytokines, and stained by a three-layer (polyclonat Abs) or four- 
layer (mAbs) PAP method. Sections were incubated overnight with 
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primary antibodies at 4~  followed by incubations at room tem- 
perature with bridging antibodies,  PAP complexes, and the sub- 
strate, diaminobenzidine, dissolved in a 1 M imidazole-0.1  M Tris 
buffer, pH 7.6. Labeled cells within 20 high-power fields (x400) 
per section per rat were assessed with the aid of an ocular grid 
micrometer.  Cytokine and endothelial labeling were judged semi- 
quantitatively,  due to the presence of extraceUular (cytokines) or 
continuous  (endothelium)  labeling,  as  <1%,  <5%,  10-20%, 
20-50% or >75% of the cells indicated. Ig deposition was assessed 
semiquantitatively by end-titer analysis of the primary anti-rat IgG 
isotype-specific Ab. The specificity of labeling was assessed using 
isotype-matched mAbs or purified Ig and a control for residual en- 
dogenous peroxidase  activity in  each  experiment.  In  addition, 
specificity of cytokine staining was confirmed by antibody absorp- 
tion with corresponding recombinant proteins using IL-4 (204-IL; 
Genzyme Corp.), II.-10 (417-ML; R&D Systems, Inc.), or IFN-3' 
(courtesy  of Dr.  P. van der Meide) (9-12). 
Results 
A  Single Injection of CTLA4Ig on Day 2 After Transplanta- 
tion Induces Donor-specific Acceptance of  Renal Allografts.  LEW 
recipients of MHC-incompatible WF renal allografts received 
a single i.p.  injection of CTLA4Ig (0.5  mg) either on the 
day of or on day 2 after transplantation.  This protocol was 
selected based on our recent data in the rat cardiac allograft 
model (7). Control animals were untreated or received a single 
injection of control human Ig (0.5 mg i.p.). While all con- 
trol untreated animals, and animals treated with a single in- 
jection of control Ig on day 2 after transplantation, died on 
day 8.9  +  1.2 (n  ~-  7) and day 6.2  _+  1.7 (n  =  6), respec- 
tively, six out of seven animals that received a single injec- 
tion of CTLA4Ig  on day 2  after transplantation  survived 
~'60-100 d (Fig. 1). By contrast, only two out of seven animals 
that received a single injection of CTLA4Ig on the day of 
engraftment survived >100 days; the remainder of the animals 
1004__,IT,IT... 
-I  80- 
< 
er  60- 
I- 
Z  40- 
O  er 
UJ 
a.  20 
CONTROL 
￿9  CONTROL Ig 
￿9  DAY 0 CTL.A41g 
A  DAY 2 CTLA41g 
}  "  ￿9 
--  i  i  i 
0  20  40  6'0  80  100 
DAYS  POST  TRANSPLANT 
Figure 1.  Survival  of LEW recipients of WF renal allografts.  The con- 
trol group were unmodified  (n = 7). The control Ig group received 0.5 
mg i.p. of control human Ig (n = 6) on day 2 after transplantation. The 
day 0 CTLA4Ig and day 2 CTLA41g groups received 0.5 mg i.p. of 
CTLA4Ig on the day of engraftment (n = 7) or 2 d after transplantation 
(n  =  7), respectively. 
Tolerance to Rat Renal Allografts died within 7 d  (Fig.  1).  We then compared the effects of 
a single injection of a relatively high dose of the conventional 
immunosuppressive agent cyclosporine to that of CTLA4Ig. 
LEW rats received a single injection of 25 mg/kg cyclospo- 
rine i.m. on day 2 after transplantation.  Four out of  five animals 
died within 13 d;  the remaining animal survived >60 d. 
In our model, the renal allograft is life sustaining, and death 
of the animal occurs only with almost complete loss of graft 
function. Thus, the parameter of animal survival would not 
detect mild or even moderate degrees of acute rejection. This 
was of  particular concern since our previous work in the cardiac 
model indicated that the grafts were sustaining at least some 
degree of immunologically mediated damage (7). Therefore, 
we assessed renal allograft function more quantitatively by 
measurement of serial serum creatinine levels. While untreated 
control animals had an elevated  serum creatinine level of 
4.99  __  1.35 mg/dl (n  =  4), compared with isograft con- 
trois (serum creatinine  =  0.69  __  0.12 mg/dl, n  --  3) on 
day 7 after transplantation, day 2 CTLA4Ig-treated animals 
had normal allograft function with a serum creatinine level 
of 0.75  __ 0.07 mg/d (n  --  6). In addition, day 2 CTLA4Ig- 
treated rats continued to have preserved renal allograft func- 
tion with serum creatinine of 0.72  _+  0.13 mg/dl at 1 mo 
and  1.05  _+  0.04  mg/dl at  3  mo.  These levels were not 
significantly different from serum creatinines of age-matched 
isograft controls (0.76  _+ 0.13 and 1.08 _+ 0.18 mg/dl, respec- 
tively). 
To test whether CTLA4Ig-treated allograft recipients sur- 
viving for >100 d were "tolerant" we rechallenged six animals 
with heterotopic WF or third-party BN cardiac allografts. 
Table 1.  Cells, Cytokines, and Other Features of Renal Allografis or Isografis in Control versus CTLA4Ig-treated  Rats 
Single dose of CTLA4Ig on day 2 
Untreated  controls 
day 7  day 7  day >100 
Isograft controls 
day 7 
Histology (CD45)  Dense interstitial  Marked interstitial  Minor interstitial  Few interstitial MNC 
MNC infiltrate,  MNC infiltrate but  MNC but moderate 
with severe  no vasculitis or  perivascular MNC 
tubulitis and  tubulitis  aggregates 
perivascular ag- 
gregates 
T cells  ,o20-30%  MNC  "020-30% MNC  ,050%  MNC  Few MNC 
('050%  CD4 §  (>80%  CD4 §  (>80%  CD4 +) 
Macrophages  >50%  MNC  >50%  MNC  ,o50%  MNC  Few MNC 
IL-2R  5-10%  MNC  5-10%  MNC  5-10%  MNC  Negative 
ICAM-1  Dense MNC, all EC,  Weak MNC, focal  MNC  Few MNC and focal 
most tubules  EC, tubules  EC 
MHC class II  Dense MNC, focal  Weak MNC plus  Kesidual MNC  Interstitial dendritic 
EC, most tubules  focal EC  cells 
TNF-c~  >50%  interstitial  <5% MNC  Negative  Few MNC 
MNC, SM 
IL-2  5-10%  MNC  Negative  Negative  Negative 
IFN-3'  10-20%  MNC  Negative  Negative  Negative 
IL-4  <5% MNC  >50%  MNC  >50%  MNC  Negative 
IL-6  10-20%  interstitial  >50%  MNC  <5%  MNC  Few MNC 
MNC 
IL-IO  <1% MNC  10-20%  MNC  <5% MNC  Negative 
PGE2  <5% MNC  >50%  MNC  >50%  MNC  Negative 
EC, endothelial  cells; MNC, mononuclear  cells; SM, smooth muscle cells. 
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7 renal  allografts  of control  (left)  versus CTLA4Ig-treated (right)  rats. 
CTLA4Ig treatment  reduced graft leukocyte infiltration  (CD45, a and 
b) and prevented development of tubulitis and glomeruliti. While untreated 
animals showed upregulation of ICAM-1 (c and d) on leukocytes, endothelial 
cells, and tubules, including tubular brush borders, treated animals showed 
only baseline ICAM-1 expression by interstitial dendritic cells and residual 
leukocytes. Class II MHC antigens (e and f) also showed differential ex- 
pression within allografts of untreated  versus treated  hosts, in a similar 
pattern to ICAM-1.  Hematoxylin;  x630. 
These recipients exhibited donor-specific  unresponsiveness, 
since they accepted WF grafts (two animals died of surgical 
complications on days 7 and 16 with normal beating WF 
heart allografts; two other animals survived >60 and >100 d 
with normal beating WF cardiac allografts, n -- 4), but they 
acutely rejected  third-party BN grafts (survival  7 and 8 d, 
n  =  2). 
Immunohistological Studies of Renal Allografts.  We under- 
took a detailed immunohistologic  evaluation of renal allografts 
of day 2 CTLA4Ig-treated animals  harvested at  1 wk and 
>100 d after transplantation and compared them with acutely 
rejecting control grafts  from untreated animals (1 wk after 
transplantation) (Table 1 and Figs. 2 and 3). Acutely rejecting 
control renal allografts  showed a dense and diffuse intersti- 
tial mononuclear cell infiltrate with severe tubulitis, glomeru- 
litis, and vasculitis. Infiltrating mononuclear cells, which con- 
sisted of macrophages and T cells, showed evidence of immune 
activation with expression of IL-2R and considerable cytokine 
expression, including dense labeling for IFN-y and TNF-ol, 
and to a lesser extent IL-2, but lacked significant labeling for 
1I.-4 or II.-10. Evidence for functional activity of proinflamma- 
tory cytokines was indicated by upregulation of intracellular 
adhesion molecule (ICAM-1) and MHC class II on endothelial 
cells and renal tubular cells. 
Figure  3.  Immunoperoxidase  analysis of IFN-3,  and IL-4 deposition 
within renal allografts of control (day 7, left) versus CTLA4Ig-treated  (day 
7, m/ddle, and day >100, right) rats. CTLA41g treatment essentially prevented 
expression of IFN-3, (a-c) but was associated with markedly  increased 
mononuclear  cell staining for IL4 (d-f),  including  residual perivascular 
infiltrates in longterm (>100 d, f) allografts. Hematoxylin;  x630. 
Allografts from CTLA4Ig-treated animals showed persis- 
tence of a mononuclear cell infiltrate,  although this was less 
dense than that of  untreated controls. Infiltrating mononuclear 
ceils were predominantly CD4 +  . Grafts lacked evidence of 
tissue injury as evidenced by absence of tubulitis, glomeru- 
litis,  or vasculitis.  These grafts also lacked staining for the 
activation markers MHC class II and ICAM-1, as well as the 
Thl-derived cytokines IL-2 and IFN-3,. In contrast, in com- 
parison to control grafts, they showed increased staining for 
the Th2-derived cytokines IL-4 and IIA0 and PGE2. Sections 
incubated with anticytokine Abs after absorption with cor- 
responding cytokine protein were unstained, as were sections 
incubated with isotype-matched Ig. Analysis of >100-d-old 
allografts  showed minimal interstitial cellular infiltrates but 
persistent perivascular mononuclear cell accumulations. Infil- 
trates  at day >100 lacked  staining for IL-2 or IFN-% but 
showed persistent upregulation of the Th2-related cytokine 
IL-4 and, to a lesser extent, IL-10. Furthermore, both day 7 
as well as >100-d-old grafts from CTLA4Ig-treated animals 
had marked upregulation of intragraft staining for IgG1, but 
not IgG2a or IgG2b, compared with rejecting controls (data 
not shown). 
Effects of Recombinant 11.-2 on  Induction of Tolerance by 
CTLA4Ig.  In the present study, it appeared that animals 
treated with CTLA4Ig were not immunologically  unrespon- 
sive to their grafts,  in that they mounted a predominantly 
Th2-type response. Therefore, it was of interest to determine 
if systemic  IL-2  could  block tolerance  induction (9) in CTLA4Ig- 
treated animals.  To this end, 4 animals received CTLA4Ig 
on day 2 after transplantation followed by rIL-2 (Collabora- 
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starting on day 3 after transplantation. Administration of rib2 
resuhed in partial reversal of the tolerant state;  two out of 
the four animals exhibited delayed renal allograft rejection 
and died on day 40, while the other two animals survived 
>100 d. In addition, rIL-2-treated animals had higher serum 
creatinine levels at 1 wk and 1 mo (1.24  +  0.31  and 1.62 
_+ 0.33 mg/dl, respectively, n =  4) after transplantation, com- 
pared with day 2 CTLA4Ig treated animals alone (0.75  _+ 
0.07,  and 0.72  _+  0.13  mg/dl, n  =  6). 
Discussion 
In this study, we show that administration of a single dose 
of CTLA4Ig  induces  donor-specific  tolerance  of MHC- 
incompatible rat renal allografts in inbred strains. Our results 
indicate that delaying the administration of the fusion pro- 
tein after engraftment is an essential component of this im- 
munosuppressive strategy. These results confirm our earlier 
work (7), where we found that administration of donor spleno- 
cytes on the day of transplantation followed by a single dose 
of CTLA4Ig two d later induced tolerance to vascularized 
cardiac allografts. A  notable difference between those data 
and the current studies is that administration of donor cells 
was not necessary for induction of long-term renal allograft 
survival.  This finding may indicate that the kidney aUograft 
itself is supplying the alloantigenic challenge in the form of 
either passenger APC or shed allo-MHC. The former possi- 
bility is consistent with the findings of Austyn et al.  (13) 
in the mouse, which show at least I-log-fold fewer dendritic 
cells resident in cardiac compared with renal tissue. 
A novel finding of this study was the preservation of in- 
tragraft mononuclear cell infiltrates in CTLA4Ig-treated ani- 
mals in conjunction with inhibition of Thl and sparing of 
Th2 (14) cytokines. This, in conjunction with the ability of 
rlL-2  to partially restore rejection, suggests that induction 
of tolerance to renal allografts by CTLA4Ig in vivo may be 
mediated by a state of immune deviation to a predominance 
of Th2 cell function. Such "deviation" of immune responses 
to Th2 cell function has been recently reported in several ex- 
perimental models of immunologic tolerance in vivo (10, 12, 
15,  16). In  addition,  upregulation  of PGE2  in  grafts  of 
CTLA4Ig-treated animals may help prevent rejection, given 
its ability to selectively inhibit Thl-cytokine production (17), 
and its previously described association with oral tolerance 
to autoimmune encephalomyelitis (10). 
What are potential mechanisms by which CTLA4Ig could 
lead to a state of immune deviation to a Th2 response? Bous- 
siotis et al. (18) reported that B7 + B cells costimulated anti- 
CD3-activated T cells for IL-2 but not IL-4 production. McAr- 
thur and Raulet (19), using T  cell clones, also found that 
CD28 stimulation was not required for IL-4 production. Simi- 
larly, Tan et al. (4) showed that CTLA4Ig inhibited accumu- 
lation of IL-2 and IFN-7, but not IL-4, mRNA in the sec- 
ondary MLR.  It has  also been reported that  IL-2 may be 
required to prime naive T cells for IL-4 production, and that 
CTLA4Ig, by blocking IL-2 production, may indirectly in- 
hibit IL-4 production (20).  In vivo,  a study of the immune 
response to H. polygyrus, a nematode parasite that normally 
induces a Th2 response, showed that CTLA4Ig blocked ILo4 
production in regional lymph nodes in response to infection 
(21). Taken together with our own data, a model emerges 
in which delaying the administration of CTLA4Ig may facili- 
tate the subsequent emergence of a Th2 response. The delay 
period  of unhindered T  cell activation  may allow  initial 
costimulation of ILo2 production by Thl cells, which enables 
T cell precursors to produce IL-4. A Th2 response develops 
and persists  in the target organ and protects it from cell- 
mediated (Thl) rejection. 
Our studies do not definitely prove that the tolerant state 
induced by CTLA4Ig is mediated by Th2 cells. Such a con- 
clusion would require more detailed studies using exogenous 
administration of other cytokines and anti-cytokine Abs (such 
as anti-IL-4  or anti-IL-10).  Indeed, the inability of rlL-2  to 
fully restore rejection may reflect the need for other cytokines, 
such as IFN-7. Other approaches include cytokine "knock- 
out" animals, especially  IL-4. In addition,  the specific role 
of increased IgG1 deposition in grafts of CTLA4Ig-treated 
animals, an effect which is most likely mediated by IL-4 (22), 
needs to be investigated, as antibody-mediated "enhancement" 
may be important in prolongation of allograft survival. 
In summary, our results indicate that delayed administra- 
tion of CTLA4Ig after alloantigenic challenge induces donor- 
specific tolerance to renal allografts and inhibits Thl but spares 
Th2 cytokines in the target organ. These observations should 
have important clinical implications for the use of CTLA4Ig 
in humans. 
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